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TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission
With its strong anti-leukaemic activity and propensity for diffusion to the central nervous system (CNS), etoposide (VP-16) has been proven to be effective when combined with TBI, with or without CY, as conditioning for BMT in acute leukaemias. [1] [2] [3] The combined use of a topoisomerase inhibitor (VP-16) together with an alkylating agent (CY) in a TBI-based conditioning regimen may represent an effective approach towards virtually eliminating the leukaemic clone. 2 Most available data concern experiences in adult patients, while little information is available in children. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, a recent study published in this journal, proved the feasibility and efficacy of TBI-VP 16-CY in paediatric patients with different types of acute leukaemias at various stages. 10 Our single-centre experience confirms the safety and efficacy of this conditioning regimen in children with ALL in 2nd CR, demonstrated by the transplantedrelated mortality (TRM) and disease-free survival (DFS) estimations.
Between April 1995 and December 1999, 28 children with ALL in 2nd CR, underwent either allogeneic BMT from an HLA-identical sibling (12 patients) or autologous stem cell transplantation (four BM and 12 PBSC). Informed consent was obtained for all children, signed by their parents. For patients who received autologous PBSC grafts from 1997 onwards, peripheral blood (CD34 + ) progenitor cells were selected adopting a new two-step negative purification method. 11 All patients were given intensive chemotherapy first-line protocols at diagnosis, according to BFM schedules. 12, 13 Site of relapse among patients undergoing allogeneic BMT was BM in six cases, BM plus CNS in two, BM plus testis in one and isolated CNS in three cases. In the autologous transplantation group, site of relapse among patients undergoing PBSC was BM in six, BM plus CNS in one, BM plus other sites (eyes or testis) in two cases, CNS isolated in one case and testis isolated in two cases, and among those undergoing ABMT was BM in two cases and BM plus CNS in two cases. from diagnosis to relapse was 26 months (range 11-102 months) and 36 months (range 15-78 months) for allogeneic and autologous transplantation, respectively. All patients underwent second-line chemotherapy after relapse, based on an induction schedule with idarubicin and Ara-C 14 and a 2 to 3 month consolidation course according to BFM chemotherapy protocols. 15 Median age at transplantation was 8 years and the male: female ratio was 17:11. The following schedule was adopted: TBI: 200 cGy twice a day, for 3 consecutive days, on days −7, −6, −5 before transplant (total dose 12 Gy); VP-16: 60 mg/kg once daily i.v. as a 4 to 8 h infusion, on day −4; CY: 50 mg/kg once daily i.v., for 2 consecutive days, on days −3 and −2 (total dose 100 mg/kg). All patients who underwent allogeneic BMT received CsA at a dose of 3 mg/kg/day by continuous i.v. infusion, as GVHD prophylaxis. Median time to myeloid engraftment (ANC Ͼ500/l) was 13 days for both allogeneic and autologous transplants. Median time to platelet engraftment (platelets Ͼ25 000/l) was 16 and 18 days for allogeneic and autologous transplantation, respectively. At the end of April 2000, 10/12 allografted patients (83.3%) were alive in CR (with a median observation time of 26 months, range 5-49 months), which results in a DFS of 80.2 at 2 years (standard error 12.8); one patient relapsed and died 1 year after transplantation, and another died 14 months after BMT due to multiple-organ failure caused by extensive chronic GVHD and thrombotic thrombocytopenic purpura. Eleven out of 16 autografted patients (68.7%) are alive in CR (with a median observation time of 24 months, range 6-36 months), which results in a DFS of 62.5 at 2 years (standard error 13.9); four patients relapsed and died (2/12 who received PBSC and 2/4 who underwent ABMT); another patient relapsed after autologous PBSC transplant and underwent a second unrelated BMT, but died from veno-occlusive disease. Overall, 9/12 patients who received autologous PBSC grafts are alive in CR with the same observation time as the whole autografted group. TRM occurred in 1/12 patients (8.3%) undergoing allogeneic BMT and in no children undergoing autologous transplantation. Transplant-related toxicity was evaluated according to the Bearman criteria: grade II mucositis requiring prolonged continuous infusion of narcotic analgesics occurred in 30% of patients; transient haemorrhagic cystitis was observed in 7% of patients. None of the allografted patients developed grade III or IV acute GVHD, although one patient developed aggressive and extensive chronic GVHD, which contributed to her death.
In this small series of children with ALL in 2nd CR, the TBI-VP16-CY regimen proved to be safe and effective for both autologous and allogeneic transplant. Studies conducted by Brown et al 3 and Giralt et al 5 observed relatively high regimen-related toxicity and mortality rates in adult patients undergoing allogeneic BMT for haematological diseases. However, in our experience, similar to that recently reported by Duerst et al, 10 the addition of VP16, administered by short duration infusion, to TBI-CY did not increase toxicity or TRM: in particular, we did not see any cases of pulmonary toxicity, which had been a major problem in previously published studies. 3, 5 In the current study, the situations of haematological remission and good clinical status at transplantation together with quick VP-16 infusion could represent the major reasons for the low TRM. In our series most of the children allografted were high-risk patients because of the time of relapse. They had been intensively treated with first-line chemotherapy and, despite that, developed relatively early relapse (median time 26 months after diagnosis), as stated by BFM risk criteria: 83.3% (10 out of 12 patients) are alive in CR with a median follow-up of 26 months.
With regard to the autografted children who presented a relatively late pre-transplant relapse (median time of 36 months after diagnosis), 68.7% are alive in CR with a median follow-up of 24 months. As regards the autologous PBSC transplantation, we cannot exclude a positive impact of both conditioning regimen and double negative selection adopted in an unselected population of relapsed ALL cases. 16 Overall, this experience can be positively compared with our previously published data regarding high-dose vincristine, fractionated TBI and CY as conditioning for allogeneic and autologous BMT in childhood ALL in 2nd CR, 17 although the current study is based on a different design, different EFS interval analysis and different clinical end points. In our previous multicentre study, 75 patients (46 allogeneic BMT and 29 ABMT, median age of 5.5 years), with early pre-transplant relapse (median 1st CR length of 26 and 25 months for allogeneic and autologous BMT, respectively) were evaluated; the overall 3-year EFS for patients who experienced a bone marrow relapse before transplant was 58.2% and 27.6% for allogeneic BMT and ABMT, respectively.
Even though many different combinations of drugs have been used as conditioning for ALL patients in 2nd CR (such as thiotepa, Ara-C, melphalan and busulfan), with or without TBI, no dramatic improvement has been observed in the past. [18] [19] [20] More recent data clarified the relevance of a graft-versus leukaemia (GVL) effect in reducing relapse after allogeneic BMT. 21, 22 It is probable that only by combining a conditioning regimen which effectively eradicates the leukaemic clone (without increasing toxicity) with an Bone Marrow Transplantation acceptable grade of GVHD able to induce an optimal GVL effect, will it be possible to improve DFS in the future.
In conclusion, despite the fact that our data appear promising, we are aware that only a larger multicentre prospective randomised study could really demonstrate the benefit of the TBI-VP16-CY regimen in children with ALL in 2nd CR, vs a standard regimen with TBI and CY or a schedule with TBI-etoposide combination. 
